Showing 1301-1310 of 2145 results for "".
Advances in Wound Care
https://practicaldermatology.com/conferences/maui-derm-2022/maui-derm-2022-video/20040/Robert S. Kirsner, MD, PhD discusses the latest in wound healing science and resulting changes in how leading wound care experts are approaching patient care. From innovative products to greater understanding of the science, there are many options to help patients heal.Scientifically Speaking: The Truth About Skincare
https://practicaldermatology.com/videos/scientifically-speaking/scientifically-speaking-the-truth-about-skincare/19876/From workhorse ingredients like antioxidants and retinol to newer molecules that address pigmentation and aging, there is a lot of noise in the skincare marketplace. And that's without talking about "natural" formulations. Joel L. Cohen, MD gets to the heart of the science, in a converDermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-cosmetic-surgery-forum-highlights-leo-focuses-on-ad/19703/New treatments and medical controversies take center stage at Cosmetic Surgery Forum as the meeting moves to Nashville in its 11th Year. Leo Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal Phase 3 studies for the treatment of adults with moderate-to-severe atopInitiating Biologics
https://practicaldermatology.com/topics/psoriasis/initiating-biologics/19986/Kara S. Gooding, MMS, PA-C offers an overview of a panel discussion about initiating treatment with biologics. The panel shared real-world applications, plus tips on lab monitoring, managing side effects, and choosing the right biologic.Scientifically Speaking: Diagnosing and Treating Hair Loss, Part 2
https://practicaldermatology.com/videos/scientifically-speaking/scientifically-speaking-diagnosing-and-treating-hair-loss-part-2/19958/From PRP to surgical updates and long-standing interventions, there are many options to address hair loss. It's essential to know the risks and benefits of treatments, including combinations. Host Joel L. Cohen, MD discusses options for hair loss with Marc Avram, MD, Cheryl Burgess, MD, and ReenDermWireTV: ASDS Meeting Highlights; Daxxify Data; PA Week
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-asds-meeting-highlights-daxxify-data-pa-week/20147/ASDS speakers address aesthetic advancements, skin cancer, and DEI with Joel L. Cohen, MD, Sherrif Ibrahim, MD, and Jeanine Downie, MD. On the heels of FDA approval of Revance’s Daxxify, data published in the Aesthetic Surgery Journal demonstrate the efficacy of DaxibotulinumtoxinA fHair Care Trends and Treatment Advances
https://practicaldermatology.com/conferences/aad-summer-2021/hair-care-trends-and-treatment-advances/19970/Ronda S. Farah, MD shares highlights from the session she and co-panelists presented on technological advancements in the management of scalp disease. They cover the role of artificial intelligence in monitoring patients, hair cosmetic trends, lasers and platelet rich plasma in 2021, novel technologDermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine.Best Practices: Allan Wirtzer, MD on Leadership
https://practicaldermatology.com/topics/practice-management/best-practices-allan-wirtzer-md-on-leadership/18592/Sometimes the most important role of a physician is leader. Whether in your practice or for your specialty overall, doctors must lead the charge forward. In this edition of Best Practices, host Joel L. Cohen, MD talks to Allan S. Wirtzer, MD about issues affecting medicine, including coding, and theDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility